SEPN.NASDAQSepterna, INC

8-K: Septerna Reports Q3 2026 Results, Pipeline Advances

Sentiment:

Quarterly Results


Septerna, Inc. announced third quarter 2026 financial results and business highlights, detailing progress in its clinical trials for SEP-479 and SEP-204, alongside a robust cash position extending runway into mid-2029.

Worse than expectedRevenue for the third quarter of 2026 decreased to $18.9 million compared to $21.5 million in the same period of 2025.Research and development expenses increased significantly to $36.6 million from $24.3 million year-over-year.The company reported a net loss of $26.6 million for the quarter, a substantial shift from a net income of $8.2 million in the prior year's quarter.

Summary

  • Septerna, Inc. reported financial results for the third quarter ended September 30, 2026.
  • The company highlighted progress in its clinical pipeline, including ongoing Phase 1 trials for SEP-479 (PTH1R agonist) and the selection of SEP-204 (TSHR NAM) as a development candidate.
  • Phase 1 data for SEP-479 is expected in Q1 2027, and a Phase 1 trial for SEP-204 is planned to initiate in Q1 2027.
  • The company reported a cash, cash equivalents, and marketable securities balance of $565.2 million as of September 30, 2026, with an expected cash runway extending at least into mid-2029.
  • Revenue for the quarter was $18.9 million, a decrease from $21.5 million in the same period last year.
  • Research and development (R&D) expenses increased to $36.6 million from $24.3 million year-over-year.
  • The company reported a net loss of $26.6 million for the quarter, compared to a net income of $8.2 million in Q3 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant pipeline progress and a strong cash position, though revenue declined year-over-year and R&D expenses increased.

Positives

  • Strong cash position of $565.2 million as of September 30, 2026, providing an expected cash runway through mid-2029.
  • Advancement of the SEP-479 program with Phase 1 SAD/MAD data expected in Q1 2027.
  • Selection of SEP-204 as a development candidate for Graves disease and thyroid eye disease, with Phase 1 initiation planned for Q1 2027.
  • Preclinical data for SEP-204 demonstrated potent and selective TSHR inhibition and positive effects in animal models.
  • Progress in the collaboration with Novo Nordisk, with Novo assuming responsibility for a development candidate and initiating IND-enabling studies.
  • Total of $13 million in research milestones achieved under the Novo collaboration to date.

Negatives

  • Revenue decreased to $18.9 million for Q3 2026 from $21.5 million in Q3 2025.
  • Research and development expenses increased significantly to $36.6 million in Q3 2026 from $24.3 million in Q3 2025.
  • Reported a net loss of $26.6 million for Q3 2026, a shift from a net income of $8.2 million in Q3 2025.

Risks

  • Risks associated with Septerna's product candidates successfully entering and advancing through clinical trials, including uncertainties related to INDs and regulatory approvals.
  • Risks related to clinical development outcomes, including unexpected safety or efficacy findings.
  • Preclinical study results, including long-term toxicology studies, may not be predictive of future clinical outcomes.
  • Risks related to the timing of initiating clinical studies and future availability of clinical data.
  • Risks related to the scope of protection Septerna can establish and maintain for intellectual property rights.
  • Risks related to Septerna's ability to identify and enter into future license agreements and collaborations.
  • General economic, industry, and market conditions.

Future Outlook

Septerna anticipates Phase 1 clinical data for SEP-479 in Q1 2027 and plans to initiate a Phase 1 trial for SEP-204 in Q1 2027. The company expects its current cash position to fund operations at least into mid-2029. The Novo Nordisk collaboration is advancing with a development candidate entering IND-enabling studies.

Management Comments

  • "We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves disease and thyroid eye disease," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna.
  • "With Phase 1 data for SEP-479 and the initiation a Phase 1 trial of SEP-204 expected in the first quarter of 2027, we are moving closer to realizing our ambition to translate our GPCR expertise into differentiated oral medicines for patients with significant unmet needs."

Industry Context

StockSavvy.ai notes that Septerna's focus on GPCR drug discovery aligns with a significant trend in the pharmaceutical industry, where targeting these receptors remains a key strategy for developing novel therapeutics across various disease areas. The company's progress in rare diseases like hypoparathyroidism and autoimmune conditions like Graves' disease reflects the industry's ongoing pursuit of treatments for conditions with high unmet medical needs.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Medical OfficerNARajiv Patni, M.D.August 2026Appointment to lead research, development, regulatory, and medical affairs organizations.

Stakeholder Impact

  • Shareholders: The increased R&D spending and net loss may be viewed negatively, but the strong cash position and pipeline progress offer potential future value.
  • Employees: Continued investment in R&D and pipeline advancement suggests ongoing employment opportunities.
  • Partners (Novo Nordisk): Progress in the collaboration is positive for both parties, with Novo assuming responsibility for a development candidate.

Next Steps

  • Complete Phase 1 clinical trial of SEP-479 and report SAD/MAD data in Q1 2027.
  • Initiate Phase 1 clinical trial for SEP-204 in Q1 2027.
  • Continue to evaluate capital-efficient, signal-finding clinical studies of SEP-631.
  • Advance oral small molecule programs for obesity, type 2 diabetes, and other cardiometabolic diseases under the Novo collaboration.
  • Continue to advance wholly owned discovery-stage programs.

Key Dates

DateDescription
March 2026Positive Phase 1 results reported for SEP-631.
July 2025Global collaboration with Novo Nordisk initiated.
August 2026Appointment of Rajiv Patni, M.D., as Chief Medical Officer.
September 30, 2026End of the third quarter for financial reporting.
November 09, 2026Date of the Form 8-K filing and press release.
Q1 2027Expected SAD/MAD data for SEP-479.
Q1 2027Anticipated initiation of Phase 1 clinical trial for SEP-204.
mid-2029Expected minimum cash runway.

Recommendation

hold

The company shows promising pipeline development and a strong cash runway, which are positive indicators. However, the year-over-year decline in revenue, increased R&D expenses, and shift from net income to a net loss warrant a cautious 'hold' rating until further clinical data and revenue growth materialize.

Keywords

biotechnology, clinical-stage, GPCR, drug discovery, hypoparathyroidism, Graves disease, thyroid eye disease, mast cell

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.